Clinical trials: Human Immunodeficiency Virus I Infection
E Cigarette Use, Vaping
Acute Effects of TCIG vs ECIG in PLWH
Randomized controlled trial of acute use of electronic cigarette or tobacco cigarette on parameters of ventricular repolarization and inflammation/oxidative stress.
- Conditions
- E Cigarette Use, Vaping, Smoking, Tobacco Smoking
- Trial name
- NCT04568395
- Testing
- TCIG, ECIG
- Where
- 2 sites in United States
- Volunteers
- 37 people
- Sponsor
- University of California, Los Angeles
Healthy Subjects, Infection, Human Immunodeficiency Virus
DDI Study of Etravirine and GSK1265744
The primary objective of this study is to compare steady-state plasma PK, safety and tolerability of GSK1265744 with and without etravirine
- Trial name
- NCT00920296
- Testing
- GSK1265744
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Hepatitis C Infection, HIV Infection
A Study to Assess the Safety of HIV and Hep C Vaccine Candidates When Given Separately or in Combination
This study is aimed at assessing the safety of candidate Hepatitis C vaccines AdCh3NSmut/MVA-NSmut and HIV vaccines ChAdV63.HIVconsv/MVA.HIVconsv when administered separately or in combination to healthy volunteers.
- Trial name
- NCT02362217
- Testing
- AdCh3NSmut1, MVA-NSmut, ChAdV63.HIVconsv
- Where
- United Kingdom
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- University of Oxford
HIV Infections, TB
A Study of MVA85A, in Asymptomatic Volunteers Infected With TB, HIV or Both
This study is designed to evaluate the safety of MVA85A in asymptomatic volunteers in South Africa who are infected with M.tb, HIV or both.
- Trial name
- NCT00480558
- Testing
- MVA 85A
- Where
- South Africa
- Volunteers
- 48 people
- Sponsor
- University of Oxford
Infection, Human Immunodeficiency Virus
A Study to Evaluate the Effects of Calcium Carbonate and Ferrous Fumarate on Pharmacokinetics of Dolutegravir in Healthy Adult Subjects
Human immune virus (HIV) infected subjects may take mineral supplements in combination with their antiretroviral medications. Calcium and Iron supplementations are commonly used and both of these have the potential to interact…
- Trial name
- NCT01762995
- Testing
- Dolutegravir 50 mg, Calcium Carbonate 1200 mg, Ferrous Fumarate 324 mg
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Tuberculosis
Study of Pre-clearance of Latent Tuberculosis Infection And BCG Revaccination
The purpose of this research is to further study the tuberculosis (TB) vaccine, Bacillus Calmette Guérin (BCG). The goal of this study is to evaluate whether the BCG vaccine is more effective in preventing TB in adults if it is…
- Trial name
- NCT01119521
- Testing
- BCG strain Danish, Isoniazid
- Where
- South Africa
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV-infection
Phase I, Open Label Dose Escalation Study to Evaluate Safety of iHIVARNA-01 in Chronically HIV-infected Patients
The main purpose of the study is to evaluate the safety and to establish the recommended dose of iHIVARNA-01 as a new therapeutic vaccine against HIV
- Trial name
- NCT02413645
- Testing
- TriMix_100, TriMix_300, 600μg mRNA (300 μg HIV mRNA+300 μg TriMix mRNA)
- Where
- Spain
- Volunteers
- 21 people
- Sponsor
- Judit Pich Martínez
HIV Infections
A Phase I/II Safety and Immunogenicity Trial of UBI Microparticulate Monovalent (HIV-1 MN) Branched Peptide Vaccine in HIV-1 Seronegative Human Subjects
To evaluate the safety and immunogenicity of a combination of microparticulate monovalent HIV-1 MN synthetic branched peptide candidate vaccine for oral administration and monovalent HIV-1 MN synthetic branched peptide vaccine in…
- Trial name
- NCT00002428
- Testing
- HIV-1 Peptide Vaccine, Microparticulate Monovalent, rgp120/HIV-1MN Monovalent Octameric V3 Peptide Vaccine
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- United Biomedical
HIV Infections, HIV Seronegativity
A Phase I Clinical Trial to Evaluate: Part A. The Safety of MTP-PE/MF59 Adjuvant Emulsion. Part B. The Safety and Immunogenicity of Env 2-3, a Yeast Derived Recombinant Envelope Protein of Human Immunodeficiency Virus-1, in Combination With MTP-PE/MF59
To evaluate the safety of a fixed antigen dose with an increasing dose of adjuvant (MTP-PE/MF59, a substance to enhance the immune response to vaccine) in volunteers. To evaluate local and systemic reactions (Part A).
- Trial name
- NCT00000972
- Testing
- MTP-PE/MF59, Env 2-3
- Where
- 3 sites in United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infection
Observational Study of the Therapeutic Study of Recombinant HIV-1 TAT
The results of the Phase I Safety and Immunogenicity Trial of Recombinant HIV-1 Tat (ISS P-001 and ISS T-001) indicate that the vaccine based on the recombinant Tat protein is safe, well tolerated and immunogenic.
- Trial name
- ISS OBS T-001 (NCT01024595)
- Where
- 3 sites in Italy
- Volunteers
- 24 people
- Sponsor
- Istituto Superiore di Sanità
HIV Infection
Capravirine to Treat Children With HIV Infection
This study will test the safety, side effects and anti-HIV activity of different doses of capravirine in children and adolescents with HIV infection.
- Trial name
- NCT00006519
- Testing
- Capravirine
- Where
- United States
- Volunteers
- 96 people
- Sponsor
- National Cancer Institute (NCI)
HIV Infections
A Study of the Safety and Effectiveness of a Chickenpox Vaccine in HIV-Infected Children
The purpose of this study is to see if it is safe to give Varivax to HIV-positive children and whether it protects children from infection.
- Trial name
- NCT00000837
- Testing
- Varicella Virus Vaccine (Live)
- Where
- 25 sites in United States
- Volunteers
- 127 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Behavioral Intervention, Viral Suppression of HIV Infection
Reactive Driven Support for Treatment, Adherence, Resilience, and Thriving (reSTART) Clinical Trial
Men who are living with HIV and use stimulants face many challenges and barriers that may interfere with remembering to take their HIV medication.
- Conditions
- Behavioral Intervention, Viral Suppression of HIV Infection, ART Adherence
- Trial name
- reSTART (NCT07125235)
- Testing
- reSTART Objective Adherence Self-Monitoring and Postive Affect mHealth Intervention, urine tenofovir point-of-care self-test
- Where
- United States
- Volunteers
- 270 people
- Sponsor
- University of California, San Francisco
HIV Infections
An Open Trial Combining Zidovudine, Interferon-alfa, and Recombinant CD4-IgG With Transplantation of Syngeneic Bone Marrow and Peripheral Blood Lymphocytes From Healthy gp160-Immunized Donors in the Treatment of Patients With HIV Infection
To restore immunologic function and virus-free state in HIV-infected patients. Based on previous studies showing temporary improvement in immune function in HIV-infected patients using peripheral lymphocyte transfers and bone…
- Trial name
- NCT00000647
- Testing
- CD4-IgG, Zidovudine, Interferon alfa-n1
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV-1-infection
Study for Evaluation of the Safety, Pharmacokinetics, and Antiviral Activity of UB-421 Subcutaneous Formulation in HIV Infected Adults
UB-421 subcutaneous formulation (UB-421 SC) is developed to provide HIV infected patients a more convenient drug delivery method.
- Trial name
- NCT04620291
- Testing
- UB-421 SC
- Volunteers
- 18 people
- Sponsor
- United BioPharma
HIV
Oral Auranofin for Reduction of Latent Viral Reservoir in Patients With HIV Infection
The main purpose of the study is to evaluate the safety of oral auranofin, a gold compound, in patients with HIV infection whose viral load has been suppressed by antiretroviral therapy for no less than 3 years and have a CD4+…
- Trial name
- Goldrake (NCT02176135)
- Testing
- Auranofin
- Where
- United States
- Sponsor
- Vaccine and Gene Therapy Institute, Florida
Infection, Human Immunodeficiency Virus
Effect of Rifampin (RIF) on the Pharmacokinetics (PK) of Oral Cabotegravir (CAB) in Healthy Subjects
CAB is an integrase inhibitor that is currently in Phase 2 clinical trials for the treatment and prevention of human immunodeficiency virus-1 (HIV-1) infection.
- Trial name
- NCT02411435
- Testing
- CAB, RIF
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Healthy Subjects, Infection, Human Immunodeficiency Virus
Drug Interaction Study of Darunavir/Ritonavir and Lopinavir/Ritonavir on GSK2248761 PK and CYP450 Probe Drugs
The purpose of this study is to evaluate the effect of GSK2448761 on CYP450 metabolic probes and to evaluate the 2-way interaction between GSK2448761 and two ritonavir-boosted protease inhibitors that are commonly used in…
- Trial name
- NCT00920088
- Testing
- darunavir/ritonavir, lopinavir/ritonavir, Midazolam
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Tuberculosis
A Phase I Study to Evaluate Safety and Immunogenicity of AERAS 404 (C-011-404)
This Phase I study will be conducted as a randomized, placebo-controlled, double-blind, dose-escalation study in four groups of healthy adult male and female subjects who are BCG-vaccinated, HIV-negative, and have no evidence of…
- Trial name
- C-011-404 (NCT02109874)
- Testing
- AERAS-404 (mcg H4/nmol IC31), Sterile buffer containing 10 mmol/L tris and 169 mmol/L NaCl
- Where
- South Africa
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Aeras
Human Immunodeficiency Virus
A Safety Study Of A Single Vaginal Administration Of P2G12 Antibody In Healthy Female Subjects
The purpose of this study is to assess the safety and tolerability of intravaginal administration of P2G12. 11 subjects will receive P2G12/placebo. Three subjects in Group 1 will receive up to 7mg of P2G12, or placebo.
- Trial name
- NCT01403792
- Testing
- P2G12
- Where
- United Kingdom
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- University of Surrey